Evaxion Unveils EVX-04 Cancer Vaccine, Significantly Inhibiting Tumor Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Source: Globenewswire
- Vaccine Development Progress: Evaxion's EVX-04 vaccine successfully induces specific T-cell responses and effectively inhibits tumor growth in preclinical models, demonstrating its potential to improve treatment options for acute myeloid leukemia (AML) patients.
- Broad Antigen Coverage: The vaccine identifies and selects 16 non-conventional endogenous retrovirus (ERV) tumor antigen fragments through the AI-Immunology™ platform, ensuring broad coverage across different patients' tumors, thereby enhancing the likelihood of immune recognition.
- Market Demand Alignment: As AML is characterized by high mortality rates and limited existing treatment options, the introduction of EVX-04 not only addresses the urgent need for new therapies but also presents significant commercial opportunities for Evaxion.
- Innovative Technology Application: The
Get Free Real-Time Notifications for Any Stock
Monitor tickers like EVAX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on EVAX
Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.550
Low
10.00
Averages
12.33
High
16.00
Current: 3.550
Low
10.00
Averages
12.33
High
16.00
About EVAX
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
Continue Reading
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
Continue Reading